We use cookies for a better user experience. Read our Privacy Policy

I Agree

Biosimulation Market Forecast Report, 2020-2030

Biosimulation Market (Offering Type: Software and Services; Application: Drug Discovery, Drug Development, and Others; and End User: Contract Research Organization, Pharmaceutical & Biotechnology Companies, Research Institutes, Regulatory Institutes, and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030

Progress in Software Engineering to Improve Development of Biosimulation Models

Advancements across various facets of the medical sector have occurred at a rapid pace over the past couple of decades, due to technological innovations and research activities. The development of new drugs for a range of medical diseases and conditions has shifted gears over the past few years due to which, the demand for biosimulation has witnessed unprecedented growth– a factor that is expected to boost the growth of the biosimulation market during the assessment period. Biosimulation is increasingly being used in drug discovery and drug development applications, including target identification & validation, lead identification & optimization, and pre-clinical testing of new drugs.

Players operating in the drug development sector are increasingly focusing on deploying various strategies to minimize monetary loss and financial costs upon failure of a drug therapy. At present, drug development companies and researchers continue to find the most effective way to bridge the gap between clinical medicine & drug development and patient response. Several new projects have entered the biosimulation market that primarily aim to improve drug development and delivery for a range of medical diseases and conditions. Advancements in the software technology and advent of artificial intelligence are likely to have a strong influence on the overall growth of the global biosimulation market during the assessment period.

At the back of these factors, the global biosimulation market is projected to reach a market value of US$ 7 Bn by the end of 2030. A number of market players are increasingly focusing on developing biosimulation platforms to gain a competitive edge in the current market landscape.

Request a sample to get extensive insights into the Biosimulation Market

Increasing Demand for Biomedical Simulations to Drive Global Market

Recent advancements in the development of biomedical simulations have played an imperative role in boosting the overall growth of the global biosimulation market. Biosimulations are increasingly being used to assess diseases, engineer cells, and model cellular processes. Market players that are currently operating in the biosimulation market are focusing on enhancing the quality of biosimulations by introducing simulation models by leveraging tools and practicing utilization in software engineering. The model engineering trend has gained considerable momentum in the recent past due to which, the global biosimulation market is on the course to exhibit an impressive growth rate during the assessment period.

Progress in software engineering is expected to largely benefit the development of biosimulation models in terms of construction, design, testing, error checking, etc. Market players are anticipated to address the current underlying issues pertaining to biosimulation such as readability, reproducibility, and reuse. Advancements in model engineering techniques are likely to play an essential role in the overall development of the global biosimulation market during the assessment period.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Market Players Focus on Expanding Services, Launching New Biosimulation Platforms to Gain Advantage

Sensing the growing interest in biosimulation, a number of players involved in the current biosimulation market are focusing on expanding their operations and services to gain competitive edge. For instance, Switchback Medical, one of the top tier medical device contract design and manufacturing companies announced that the company is likely to expand its services by creating a new division– Switchback BioSim Innovations. With the expansion, the company aims to improve its market position by offering dynamic biosimualtion model development, physical training, and cell culture services.

In April 2020, OnScale and LEXMA entered a partnership– a move wherein both companies are expected to leverage AI and cloud simulation, and launch effective biosumualation solutions to improve patient outcome.

Stuck in a neck-to-neck competition with other brands? Request a custom report on Biosimulation Market

Market Players Explore Potentials of Biosimulation to Combat COVID-19 Pandemic

The outbreak of the novel COVID-19 pandemic is expected to have a low impact on the global biosimulation market. Research and development activities are likely to continue in full swing amid the COVID-19 crisis, as researchers and medical experts explore the potentials of biosimulation to curb the transmission of the novel coronavirus. Thus, the demand for biosimulation solutions and platforms is anticipated to witness steady growth.

Analysts’ Viewpoint

The global biosimulation market is expected to expand at an impressive CAGR of 13.3% during the forecast period. Advancements in technology, increasing focus on improving drug development & discovery, growing adoption of artificial intelligence, and rising emphasis on improving model engineering solutions are factors projected to drive the global market. In addition, research and development activities, along with increasing investments toward the same would play a key role in fueling the global biosimulation market growth during the assessment period.  

Biosimulation Market: Overview

  • The global biosimulation market was valued at US$ 1.8 Bn in 2019 and is projected to expand at a high CAGR from 2020 to 2030
  • Biosimulation can be defined as computer-aided mathematical simulation of the biological processes, which forms an integral part of the human biology system. Biosimulation offers model-based prediction of the behavior and the dynamics of biological systems.
  • The global biosimulation market is driven by increase in adoption of biosimulation in drug discovery and development by regulatory bodies, rise in failure rates of drugs in the late clinical trial phases, surge in spending on research & development by pharmaceutical and biotechnology companies, and increase in awareness about the advantages of biosimulation
  • Additionally, usage of biosimulation technologies in testing the hypothesis of using drugs for a new indication or disease contributes to the growth of the market

Biosimulation Market: Segmentation

  • The global biosimulation market has been segmented based on offering type, application, end user, and region
  • In terms of offering type, the global biosimulation market has been categorized into software and services. The software segment has been split into PK/PD modeling & simulation, PBPK modeling & simulation, trial simulators, molecular modeling, and others.
  • Based on application, the global biosimulation market has been classified into drug discovery, drug development, and others. The drug discovery segment has been segregated into target identification & validation and lead identification & optimization.
  • Rise in usage of biosimulation and modeling technologies in drug discovery can be attributed to increase in usage of molecular modelling for the identification of effective compounds that help enhance the efficiency and reduce drug toxicity. Furthermore, role of molecular dynamics simulation in drug discovery propels the segment. The drug development segment has been bifurcated into pre-clinical testing and clinical trial.
  • In terms of end user, the global biosimulation market has been divided into contract research organization, pharmaceutical & biotechnology companies, research institutes, regulatory institutes, and others

Biosimulation Market: Regional Segmentation

  • The global biosimulation market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
  • North America dominated the global biosimulation market in 2019 and the trend is projected to continue during the forecast period
  • The biosimulation market in Asia Pacific is anticipated to expand at a high CAGR from 2020 to 2030. Growth of the market in the region can be attributed to increase in the number of regulatory agencies adopting biosimulation and rise in momentum on life sciences research, owing to favorable government policies and partly due to significant demand for innovative drugs.

Biosimulation Market: Major Players

  • The global biosimulation market is fragmented in terms of number of players. Key players operating in the global biosimulation market are
    • Certara, Dassault Systèmes S.A.,
    • Schrödinger, Inc.,
    • Simulations Plus, Inc.,
    • Rhenovia Pharma,
    • Advanced Chemistry Development, Inc.,
    • Insilico Biotechnology AG,
    • Physiomics plc,
    • Genedata AG,
    • Rosa & Co. LLC., among others
  • In June 2020, Certara launched an updated version of its Phoenix biosimulation software, which is considered the industry gold standard in pharmacokinetic/pharmacodynamic (PK/PD) and toxicokinetic modeling and simulation software. The updated version includes features to enhance efficiency, quality, and time saving required for conducting trials. This is anticipated to contribute to the growth of the biosimulation market.
  • In August 2020, Certara announced the development of biosimulation platform for COVID-19 vaccines. The company has been developing a Quantitative Systems Pharmacology (QSP) platform for COVID-19 to test vaccine candidates across multiple patient populations.

Biosimulation Market – Segmentation

Offering Type

  • Software
    •  PK/PD Modeling & Simulation
    •  PBPK Modeling & Simulation
    •  Trial Simulators
    •  Molecular Modeling
    •  Others
  • Services

Application

  • Drug Discovery
    • Target Identification & Validation
    • Identification & Optimization
  • Drug Development
    •  Pre-clinical Testing
    •  Clinical Trial
  • Others

End User

  • Contract Research Organization
  • Pharmaceutical & Biotechnology Companies
  • Research Institutes
  • Regulatory Institutes
  • Others

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

 

Biosimulation Market Forecast Report, 2020-2030

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of biosimulation market?

The global biosimulation market was worth US$ 1.8 Bn and is projected to reach a value of US$ 7 Bn by the end of 2030

What is the anticipated CAGR of the biosimulation market in the forecast period?

Biosimulation market is anticipated to grow at a CAGR of 13.3% during the forecast period

Which region is expected to project the highest market share in biosimulation market?

North America accounted for a major share of the global biosimulation market

What are the key driving factors for the growth of biosimulation market?

Biosimulation market is driven by increase in adoption of biosimulation in drug discovery and development by regulatory bodies, rise in failure rates of drugs in the late clinical trial phases

Who are the key players in the global biosimulation market?

Key players in the global biosimulation market include Certara, Dassault Systèmes S.A., Schrödinger, Inc., Simulations Plus, Inc., Rhenovia Pharma, Advanced Chemistry Development, Inc., Insilico Biotechnology AG, Physiomics plc, Genedata AG, and Rosa & Co. LLC

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Biosimulation Market

4. Market Overview

    4.1. Definition

    4.2. Market Indicators

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Biosimulation Market Value (US$ Mn) Forecast, 2018–2030

    4.5. Global Biosimulation Market Outlook

5. Key Insights

    5.1. COVID-19 Pandemics Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

    5.2. Technological Advancements

    5.3. Healthcare Industry Overview

    5.4. Key Industry Events

6. Global Biosimulation Market Analysis and Forecast, by Offering Type

    6.1. Introduction

    6.2. Global Biosimulation Market Value Share Analysis, by Offering Type

    6.3. Global Biosimulation Market Value Forecast, by Offering Type, 2018–2030

        6.3.1. Software

            6.3.1.1. PK/PD Modeling & Simulation

            6.3.1.2. PBPK Modeling & Simulation

            6.3.1.3. Trial Simulators

            6.3.1.4. Molecular Modeling

            6.3.1.5. Others

        6.3.2. Services

    6.4. Global Biosimulation Market Attractiveness Analysis, by Offering Type

7. Global Biosimulation Market Analysis and Forecast, by Application

    7.1. Introduction

    7.2. Global Biosimulation Market Value Share Analysis, by Application

    7.3. Global Biosimulation Market Value Forecast, by Application, 2018–2030

        7.3.1. Drug Discovery

            7.3.1.1. Target Identification & Validation

            7.3.1.2. Lead Identification & Optimization

        7.3.2. Drug Development

            7.3.2.1. Pre-clinical Testing

            7.3.2.2. Clinical Trial

        7.3.3. Others

    7.4. Global Biosimulation Market Attractiveness Analysis, by Application

8. Global Biosimulation Market Analysis and Forecast, by End-user

    8.1. Introduction

    8.2. Global Biosimulation Market Value Share Analysis, by End-user

    8.3. Global Biosimulation Market Value Forecast, by End-user, 2018–2030

        8.3.1. Contract Research Organization

        8.3.2. Pharmaceutical & Biotechnology Companies

        8.3.3. Research Institutes

        8.3.4. Regulatory Institutes

        8.3.5. Others

    8.4. Global Biosimulation Market Attractiveness Analysis, by Application

9. Global Biosimulation Market Analysis and Forecast, by Region

    9.1. Regional Outlook

    9.2. Introduction

    9.3. Global Biosimulation Market Value Forecast, by Region

        9.3.1. North America

        9.3.2. Europe

        9.3.3. Asia Pacific

        9.3.4. Latin America

        9.3.5. Middle East & Africa

    9.4.  Global Biosimulation Market Attractiveness Analysis, by Region

10. North America Biosimulation Market Analysis and Forecast

    10.1.  Key Findings

    10.2.  North America Biosimulation Market Value Forecast, by Offering Type, 2018–2030

        10.2.1. Software

            10.2.1.1. PK/PD Modeling & Simulation

            10.2.1.2. PBPK Modeling & Simulation

            10.2.1.3. Trial Simulators

            10.2.1.4. Molecular Modeling

            10.2.1.5. Others

        10.2.2. Services

    10.3. North America Biosimulation Market Value Forecast, by Application, 2018–2030

        10.3.1. Drug Discovery

            10.3.1.1. Target Identification & Validation

            10.3.1.2. Lead Identification & Optimization

        10.3.2. Drug Development

            10.3.2.1. Pre-clinical Testing

            10.3.2.2. Clinical Trial

        10.3.3. Others

    10.4. North America Biosimulation Market Value Forecast, by End-user, 2018–2030

        10.4.1. Contract Research Organization

        10.4.2. Pharmaceutical & Biotechnology Companies

        10.4.3. Research Institutes

        10.4.4. Regulatory Institutes

        10.4.5. Others

    10.5. North America Biosimulation Market Value Forecast, by Country, 2018–2030

        10.5.1. U.S.

        10.5.2. Canada

    10.6. North America Biosimulation Market Attractiveness Analysis

        10.6.1. By Offering Type

        10.6.2. By Application

        10.6.3. By End-user

        10.6.4. By Country

11. Europe Biosimulation Market Analysis and Forecast

    11.1.  Key Findings

    11.2.  Europe Biosimulation Market Value Forecast, by Offering Type, 2018–2030

        11.2.1. Software

            11.2.1.1. PK/PD Modeling & Simulation

            11.2.1.2. PBPK Modeling & Simulation

            11.2.1.3. Trial Simulators

            11.2.1.4. Molecular Modeling

            11.2.1.5. Others

        11.2.2. Services

    11.3. Europe Biosimulation Market Value Forecast, by Application, 2018–2030

        11.3.1. Drug Discovery

            11.3.1.1. Target Identification & Validation

            11.3.1.2. Lead Identification & Optimization

        11.3.2. Drug Development

            11.3.2.1. Pre-clinical Testing

            11.3.2.2. Clinical Trial

        11.3.3. Others

    11.4. Europe Biosimulation Market Value Forecast, by End-user, 2018–2030

        11.4.1. Contract Research Organization

        11.4.2. Pharmaceutical & Biotechnology Companies

        11.4.3. Research Institutes

        11.4.4. Regulatory Institutes

        11.4.5. Others

    11.5. Europe Biosimulation Market Value Forecast, by Country/Sub-region, 2018–2030

        11.5.1. U.K.

        11.5.2. Germany

        11.5.3. France

        11.5.4. Italy

        11.5.5. Spain

        11.5.6. Rest of Europe

    11.6. Europe Biosimulation Market Attractiveness Analysis

        11.6.1. By Product

        11.6.2. By Material

        11.6.3. By Application

        11.6.4. By Distribution Channel

        11.6.5. By Country/Sub-region

12. Asia Pacific Biosimulation Market Analysis and Forecast

    12.1.  Key Findings

    12.2. Asia Pacific Biosimulation Market Value Forecast, by Offering Type, 2018–2030

        12.2.1. Software

            12.2.1.1. PK/PD Modeling & Simulation

            12.2.1.2. PBPK Modeling & Simulation

            12.2.1.3. Trial Simulators

            12.2.1.4. Molecular Modeling

            12.2.1.5. Others

        12.2.2. Services

    12.3. Asia Pacific Biosimulation Market Value Forecast, by Application, 2018–2030

        12.3.1. Drug Discovery

            12.3.1.1. Target Identification & Validation

            12.3.1.2. Lead Identification & Optimization

        12.3.2. Drug Development

            12.3.2.1. Pre-clinical Testing

            12.3.2.2. Clinical Trial

        12.3.3. Others

    12.4. Asia Pacific Biosimulation Market Value Forecast, by End-user, 2018–2030

        12.4.1. Contract Research Organization

        12.4.2. Pharmaceutical & Biotechnology Companies

        12.4.3. Research Institutes

        12.4.4. Regulatory Institutes

        12.4.5. Others

        12.4.6.

    12.5. Asia Pacific Biosimulation Market Value Forecast, by Country/Sub-region, 2018–2030

        12.5.1. China

        12.5.2. India

        12.5.3. Japan

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Asia Pacific Biosimulation Market Attractiveness Analysis

        12.6.1. By Offering Type

        12.6.2. By Application

        12.6.3. By End-user

        12.6.4. By Country/Sub-region

13. Latin America Biosimulation Market Analysis and Forecast

    13.1.  Key Findings

    13.2. Latin America Biosimulation Market Value Forecast, by Offering Type, 2018–2030

        13.2.1. Software

            13.2.1.1. PK/PD Modeling & Simulation

            13.2.1.2. PBPK Modeling & Simulation

            13.2.1.3. Trial Simulators

            13.2.1.4. Molecular Modeling

            13.2.1.5. Others

        13.2.2. Services

    13.3. Latin America Biosimulation Market Value Forecast, by Application, 2018–2030

        13.3.1. Drug Discovery

            13.3.1.1. Target Identification & Validation

            13.3.1.2. Lead Identification & Optimization

        13.3.2. Drug Development

            13.3.2.1. Pre-clinical Testing

            13.3.2.2. Clinical Trial

        13.3.3. Others

    13.4. Latin America Biosimulation Market Value Forecast, by End-user, 2018–2030

        13.4.1. Contract Research Organization

        13.4.2. Pharmaceutical & Biotechnology Companies

        13.4.3. Research Institutes

        13.4.4. Regulatory Institutes

        13.4.5. Others

    13.5. Latin America Biosimulation Market Value Forecast, by Country/Sub-region, 2018–2030

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Latin America Biosimulation Market Attractiveness Analysis

        13.6.1. By Offering Type

        13.6.2. By Application

        13.6.3. By End-user

        13.6.4. By Country/Sub-region

14. Middle East & Africa Biosimulation Market Analysis and Forecast

    14.1.  Key Findings

    14.2. Middle East & Africa Biosimulation Market Value Forecast, by Offering Type, 2018–2030

        14.2.1. Software

            14.2.1.1. PK/PD Modeling & Simulation

            14.2.1.2. PBPK Modeling & Simulation

            14.2.1.3. Trial Simulators

            14.2.1.4. Molecular Modeling

            14.2.1.5. Others

        14.2.2. Services

    14.3. Middle East & Africa Biosimulation Market Value Forecast, by Application, 2018–2030

        14.3.1. Drug Discovery

            14.3.1.1. Target Identification & Validation

            14.3.1.2. Lead Identification & Optimization

        14.3.2. Drug Development

            14.3.2.1. Pre-clinical Testing

            14.3.2.2. Clinical Trial

        14.3.3. Others

    14.4. Middle East & Africa Biosimulation Market Value Forecast, by End-user, 2018–2030

        14.4.1. Contract Research Organization

        14.4.2. Pharmaceutical & Biotechnology Companies

        14.4.3. Research Institutes

        14.4.4. Regulatory Institutes

        14.4.5. Others

    14.5. Middle East & Africa Biosimulation Market Value Forecast, by Country/Sub-region, 2018–2030

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Middle East & Africa Biosimulation Market Attractiveness Analysis

        14.6.1. By Offering Type

        14.6.2. By Application

        14.6.3. By End-user

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1.  Market Player - Competition Matrix (by tier and size of companies)

    15.2.  Market Ranking Analysis, by Company, 2019

    15.3. Company Profiles

        15.3.1. Certara

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.1.2. Financial Overview

            15.3.1.3. Product Portfolio

            15.3.1.4. Strategic Overview

            15.3.1.5. SWOT Analysis

        15.3.2. Dassault Systèmes S.A.

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.2.2. Financial Overview

            15.3.2.3. Product Portfolio

            15.3.2.4. Strategic Overview

            15.3.2.5. SWOT Analysis

        15.3.3. Schrödinger, Inc.

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.3.2. Financial Overview

            15.3.3.3. Product Portfolio

            15.3.3.4. Strategic Overview

            15.3.3.5. SWOT Analysis

        15.3.4. Simulations Plus, Inc.

            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.4.2. Financial Overview

            15.3.4.3. Product Portfolio

            15.3.4.4. Strategic Overview

            15.3.4.5. SWOT Analysis

        15.3.5. Rhenovia Pharma

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.5.2. Financial Overview

            15.3.5.3. Product Portfolio

            15.3.5.4. Strategic Overview

            15.3.5.5. SWOT Analysis

        15.3.6. Advanced Chemistry Development, Inc.

            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.6.2. Financial Overview

            15.3.6.3. Product Portfolio

            15.3.6.4. Strategic Overview

            15.3.6.5. SWOT Analysis

        15.3.7. Insilico Biotechnology AG

            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.7.2. Financial Overview

            15.3.7.3. Product Portfolio

            15.3.7.4. Strategic Overview

            15.3.7.5. SWOT Analysis

        15.3.8. Physiomics plc

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.8.2. Financial Overview

            15.3.8.3. Product Portfolio

            15.3.8.4. Strategic Overview

            15.3.8.5. SWOT Analysis

        15.3.9. Genedata AG

            15.3.9.1.  Company Overview (HQ, Business Segments, Employee Strength)

            15.3.9.2. Financial Overview

            15.3.9.3. Product Portfolio

            15.3.9.4. Strategic Overview

            15.3.9.5. SWOT Analysis

        15.3.10. Rosa & Co. LLC.

            15.3.10.1.  Company Overview (HQ, Business Segments, Employee Strength)

            15.3.10.2. Financial Overview

            15.3.10.3. Product Portfolio

            15.3.10.4. Strategic Overview

            15.3.10.5. SWOT Analysis

List of Tables

Table 01: Global Biosimulation Market Value (US$ Mn) Forecast, by Offering Type, 2014–2025

Table 02: Global Biosimulation Market Value (US$ Mn) Forecast, by Software, 2014–2025

Table 03: Global Biosimulation Market Value (US$ Mn) Forecast, by Application, 2014–2025

Table 04: Global Biosimulation Market Value (US$ Mn) Forecast, by Drug Discovery, 2014–2025

Table 05: Global Biosimulation Market Value (US$ Mn) Forecast, by Drug Development, 2014–2025

Table 06: Global Biosimulation Market Value (US$ Mn) Forecast, by End-user, 2018–2030

Table 07: Global Biosimulation Market Value (US$ Mn) Forecast, by Region, 2018–2030

Table 08: North America Biosimulation Market Value (US$ Mn) Forecast, by Country, 2019–2030

Table 09: North America Biosimulation Market Value (US$ Mn) Forecast, by Offering Type, 2019–2030

Table 10: North America Biosimulation Market Value (US$ Mn) Forecast, by Software, 2019–2030

Table 11: North America Biosimulation Market Value (US$ Mn) Forecast, by Application, 2019–2030

Table 12: North America Biosimulation Market Value (US$ Mn) Forecast, by Drug Discovery, 2019–2030

Table 13: North America Biosimulation Market Value (US$ Mn) Forecast, by Drug Development, 2019–2030

Table 14: North America Biosimulation Market Value (US$ Mn) Forecast, by End-user, 2019–2030

Table 15: Europe Biosimulation Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019–2030

Table 16: Europe Biosimulation Market Value (US$ Mn) Forecast, by Offering Type, 2019–2030

Table 17: Europe Biosimulation Market Value (US$ Mn) Forecast, by Software, 2019–2030

Table 18: Europe Biosimulation Market Value (US$ Mn) Forecast, by Application, 2019–2030

Table 19: Europe Biosimulation Market Value (US$ Mn) Forecast, by Drug Discovery, 2019–2030

Table 20: Europe Biosimulation Market Value (US$ Mn) Forecast, by Drug Development, 2019–2030

Table 21: Europe Biosimulation Market Value (US$ Mn) Forecast, by End-user, 2019–2030

Table 22: Asia Pacific Biosimulation Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019–2030

Table 23: Asia Pacific Biosimulation Market Value (US$ Mn) Forecast, by Offering Type, 2019–2030

Table 24: Asia Pacific Biosimulation Market Value (US$ Mn) Forecast, by Software, 2019–2030

Table 25: Asia Pacific Biosimulation Market Value (US$ Mn) Forecast, by Application, 2019–2030

Table 26: Asia Pacific Biosimulation Market Value (US$ Mn) Forecast, by Drug Discovery, 2019–2030

Table 27: Asia Pacific Biosimulation Market Value (US$ Mn) Forecast, by Drug Development, 2019–2030

Table 28: Asia Pacific Biosimulation Market Value (US$ Mn) Forecast, by End-user, 2019–2030

Table 29: Latin America Biosimulation Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019–2030

Table 30: Latin America Biosimulation Market Value (US$ Mn) Forecast, by Offering Type, 2019–2030

Table 31: Latin America Biosimulation Market Value (US$ Mn) Forecast, by Software, 2019–2030

Table 32: Latin America Biosimulation Market Value (US$ Mn) Forecast, by Application, 2019–2030

Table 33: Latin America Biosimulation Market Value (US$ Mn) Forecast, by Drug Discovery, 2019–2030

Table 34: Latin America Biosimulation Market Value (US$ Mn) Forecast, by Drug Development, 2019–2030

Table 35: Latin America Biosimulation Market Value (US$ Mn) Forecast, by End-user, 2019–2030

Table 36: Middle East & Africa Biosimulation Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019–2030

Table 37: Middle East & Africa Biosimulation Market Value (US$ Mn) Forecast, by Offering Type, 2019–2030

Table 38: Middle East & Africa Biosimulation Market Value (US$ Mn) Forecast, by Software, 2019–2030

Table 39: Middle East & Africa Biosimulation Market Value (US$ Mn) Forecast, by Application, 2019–2030

Table 40: Middle East & Africa Biosimulation Market Value (US$ Mn) Forecast, by Drug Discovery, 2019–2030

Table 41: Middle East & Africa Biosimulation Market Value (US$ Mn) Forecast, by Drug Development, 2019–2030

Table 42: Middle East & Africa Biosimulation Market Value (US$ Mn) Forecast, by End-user, 2019–2030

List of Figures

Figure 01: Global Biosimulation Market Value (US$ Mn) Forecast, 2018–2030

Figure 02: Global Biosimulation Market Value Share, by Offering Type, 2019

Figure 03: Global Biosimulation Market Value Share, by Application, 2019

Figure 04: Global Biosimulation Market Value Share, by End-user, 2019

Figure 05: Global Biosimulation Market Value Share, by Region, 2019

Figure 06: Global Biosimulation Market Value Share Analysis, by Offering Type, 2019 and 2030

Figure 07: Global Biosimulation Market Attractiveness Analysis, by Offering Type, 2020–2030

Figure 08: Global Biosimulation Market Value Share Analysis, by Software, 2019 and 2030

Figure 09: Global Biosimulation Market Attractiveness Analysis, by Software, 2020–2030

Figure 10: Global Biosimulation Market Revenue (US$ Mn), by Software, 2018–2030

Figure 11: Global Biosimulation Market Revenue (US$ Mn), by Services, 2018–2030

Figure 12: Global Biosimulation Market Value Share Analysis, by Application, 2019 and 2030

Figure 13: Global Biosimulation Market Attractiveness Analysis, by Application, 2020–2030

Figure 14: Global Biosimulation Market Value Share Analysis, by Drug Discovery, 2019 and 2030

Figure 15: Global Biosimulation Market Attractiveness Analysis, by Drug Discovery, 2020–2030

Figure 16: Global Biosimulation Market Value Share Analysis, by Drug Development, 2019 and 2030

Figure 17: Global Biosimulation Market Attractiveness Analysis, by Drug Development, 2020–2030

Figure 18: Global Biosimulation Market Value (US$ Mn), by Drug Discovery, 2018–2030

Figure 19: Global Biosimulation Market Value (US$ Mn), by Drug Development, 2018–2030

Figure 20: Global Biosimulation Market Value (US$ Mn), by Others, 2018–2030

Figure 21: Global Biosimulation Market Value Share Analysis, by End-user, 2019 and 2030

Figure 22: Global Biosimulation Market Attractiveness Analysis, by End-user, 2020–2030

Figure 23: Global Biosimulation Market Value (US$ Mn), by Contract Research Organization, 2018–2030

Figure 24: Global Biosimulation Market Value (US$ Mn), by Pharmaceutical and Biotechnology Companies, 2018–2030

Figure 25: Global Biosimulation Market Value (US$ Mn), by Research Institutes, 2018–2030

Figure 26: Global Biosimulation Market Value (US$ Mn), by Regulatory Institutes, 2018–2030

Figure 27: Global Biosimulation Market Value (US$ Mn), by Others, 2018–2030

Figure 28: Global Biosimulation Market: Regional Outlook

Figure 29: Global Biosimulation Market Attractiveness Analysis, by Region, 2019 and 2030

Figure 30: Global Biosimulation Market Value Share Analysis, by Region, 2020–2030

Figure 31: North America Biosimulation Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 32: North America Biosimulation Market Value Share Analysis, by Country, 2019 and 2030

Figure 33: North America Biosimulation Market Attractiveness Analysis, by Country, 2019–2030

Figure 34: North America Biosimulation Market Value Share Analysis, by Offering Type, 2019 and 2030

Figure 35: North America Biosimulation Market Attractiveness Analysis, by Offering Type, 2020–2030

Figure 36: North America Biosimulation Market Value Share Analysis, by Software, 2019 and 2030

Figure 37: North America Biosimulation Market Attractiveness Analysis, by Software, 2020–2030

Figure 38: North America Biosimulation Market Value Share Analysis, by Application, 2019 and 2030

Figure 39: North America Biosimulation Market Attractiveness Analysis, by Application, 2020–2030

Figure 40: North America Biosimulation Market Value Share Analysis, by Drug Discovery, 2019 and 2030

Figure 41: North America Biosimulation Market Attractiveness Analysis, by Drug Discovery, 2020–2030

Figure 42: North America Biosimulation Market Value Share Analysis, by Drug Development, 2019 and 2030

Figure 43: North America Biosimulation Market Attractiveness Analysis, by Drug Development, 2020–2030

Figure 44: North America Biosimulation Market Value Share Analysis, by End-user, 2019 and 2030

Figure 45: North America Biosimulation Market Attractiveness Analysis, by End-user, 2020–2030

Figure 46: Europe Biosimulation Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 47: Europe Biosimulation Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 48: Europe Biosimulation Market Attractiveness Analysis, by Country/Sub-region, 2019–2030

Figure 49: Europe Biosimulation Market Value Share Analysis, by Offering Type, 2019 and 2030

Figure 50: Europe Biosimulation Market Attractiveness Analysis, by Offering Type, 2020–2030

Figure 51: Europe Biosimulation Market Value Share Analysis, by Software, 2019 and 2030

Figure 52: Europe Biosimulation Market Attractiveness Analysis, by Software, 2020–2030

Figure 53: Europe Biosimulation Market Value Share Analysis, by Application, 2019 and 2030

Figure 54: Europe Biosimulation Market Attractiveness Analysis, by Application, 2020–2030

Figure 55: Europe Biosimulation Market Value Share Analysis, by Drug Discovery, 2019 and 2030

Figure 56: Europe Biosimulation Market Attractiveness Analysis, by Drug Discovery, 2020–2030

Figure 57: Europe Biosimulation Market Value Share Analysis, by Drug Development, 2019 and 2030

Figure 58: Europe Biosimulation Market Attractiveness Analysis, by Drug Development, 2020–2030

Figure 59: Europe Biosimulation Market Value Share Analysis, by End-user, 2019 and 2030

Figure 60: Europe Biosimulation Market Attractiveness Analysis, by End-user, 2020–2030

Figure 61: Asia Pacific Biosimulation Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 62: Asia Pacific Biosimulation Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 63: Asia Pacific Biosimulation Market Attractiveness Analysis, by Country/Sub-region, 2019–2030

Figure 64: Asia Pacific Biosimulation Market Value Share Analysis, by Offering Type, 2019 and 2030

Figure 65: Asia Pacific Biosimulation Market Attractiveness Analysis, by Offering Type, 2020–2030

Figure 66: Asia Pacific Biosimulation Market Value Share Analysis, by Software, 2019 and 2030

Figure 67: Asia Pacific Biosimulation Market Attractiveness Analysis, by Software, 2020–2030

Figure 68: Asia Pacific Biosimulation Market Value Share Analysis, by Application, 2019 and 2030

Figure 69: Asia Pacific Biosimulation Market Attractiveness Analysis, by Application, 2020–2030

Figure 70: Asia Pacific Biosimulation Market Value Share Analysis, by Drug Discovery, 2019 and 2030

Figure 71: Asia Pacific Biosimulation Market Attractiveness Analysis, by Drug Discovery, 2020–2030

Figure 72: Asia Pacific Biosimulation Market Value Share Analysis, by Drug Development, 2019 and 2030

Figure 73: Asia Pacific Biosimulation Market Attractiveness Analysis, by Drug Development, 2020–2030

Figure 74: Asia Pacific Biosimulation Market Value Share Analysis, by End-user, 2019 and 2030

Figure 75: Asia Pacific Biosimulation Market Attractiveness Analysis, by End-user, 2020–2030

Figure 76: Latin America Biosimulation Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 77: Latin America Biosimulation Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 78: Latin America Biosimulation Market Attractiveness Analysis, by Country/Sub-region, 2019–2030

Figure 79: Latin America Biosimulation Market Value Share Analysis, by Offering Type, 2019 and 2030

Figure 80: Latin America Biosimulation Market Attractiveness Analysis, by Offering Type, 2020–2030

Figure 81: Latin America Biosimulation Market Value Share Analysis, by Software, 2019 and 2030

Figure 82: Latin America Biosimulation Market Attractiveness Analysis, by Software, 2020–2030

Figure 83: Latin America Biosimulation Market Value Share Analysis, by Application, 2019 and 2030

Figure 84: Latin America Biosimulation Market Attractiveness Analysis, by Application, 2020–2030

Figure 85: Latin America Biosimulation Market Value Share Analysis, by Drug Discovery, 2019 and 2030

Figure 86: Latin America Biosimulation Market Attractiveness Analysis, by Drug Discovery, 2020–2030

Figure 87: Latin America Biosimulation Market Value Share Analysis, by Drug Development, 2019 and 2030

Figure 88: Latin America Biosimulation Market Attractiveness Analysis, by Drug Development, 2020–2030

Figure 89: Latin America Biosimulation Market Value Share Analysis, by End-user, 2019 and 2030

Figure 90: Latin America Biosimulation Market Attractiveness Analysis, by End-user, 2020–2030

Figure 91: Middle East & Africa Biosimulation Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 92: Middle East & Africa Biosimulation Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 93: Middle East & Africa Biosimulation Market Attractiveness Analysis, by Country/Sub-region, 2019–2030

Figure 94: Middle East & Africa Biosimulation Market Value Share Analysis, by Offering Type, 2019 and 2030

Figure 95: Middle East & Africa Biosimulation Market Attractiveness Analysis, by Offering Type, 2020–2030

Figure 96: Middle East & Africa Biosimulation Market Value Share Analysis, by Software, 2019 and 2030

Figure 97: Middle East & Africa Biosimulation Market Attractiveness Analysis, by Software, 2020–2030

Figure 98: Middle East & Africa Biosimulation Market Value Share Analysis, by Application, 2019 and 2030

Figure 99: Middle East & Africa Biosimulation Market Attractiveness Analysis, by Application, 2020–2030

Figure 100: Middle East & Africa Biosimulation Market Value Share Analysis, by Drug Discovery, 2019 and 2030

Figure 101: Middle East & Africa Biosimulation Market Attractiveness Analysis, by Drug Discovery, 2020–2030

Figure 102: Middle East & Africa Biosimulation Market Value Share Analysis, by Drug Development, 2019 and 2030

Figure 103: Middle East & Africa Biosimulation Market Attractiveness Analysis, by Drug Development, 2020–2030

Figure 104: Middle East & Africa Biosimulation Market Value Share Analysis, by End-user, 2019 and 2030

Figure 105: Middle East & Africa Biosimulation Market Attractiveness Analysis, by End-user, 2020–2030

Figure 106: Global Biosimulation Market Analysis, by Top Company Ranking, 2019

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

381

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved